DepoMed Inc. Stock Upgraded (DEPO)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- DepoMed (Nasdaq: DEPO) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, solid stock price performance, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • DEPO's very impressive revenue growth greatly exceeded the industry average of 1.5%. Since the same quarter one year prior, revenues leaped by 52.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, DEPOMED INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
  • Powered by its strong earnings growth of 1128.57% and other important driving factors, this stock has surged by 154.51% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, DEPO should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 1228.5% when compared to the same quarter one year prior, rising from -$3.70 million to $41.80 million.
  • The gross profit margin for DEPOMED INC is currently very high, coming in at 91.05%. Regardless of DEPO's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, DEPO's net profit margin of 102.93% significantly outperformed against the industry.

Depomed, Inc., a specialty pharmaceutical company, focuses on developing products for pain and other conditions, and diseases of the central nervous system in the United States. DepoMed has a market cap of $788.1 million and is part of the health care sector and drugs industry. Shares are up 30.7% year to date as of the close of trading on Monday.

You can view the full DepoMed Ratings Report or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Depomed Focuses on Flagship Drug Rather Than M&A: CEO